Respiratory drug development is challenging and only 3 per cent of the drugs for which a clinical trial is started end up on the market, lower than in any other medical field. The lack of efficacy is now the most common cause of drug attrition and this appears to be a recurrent problem in respiratory diseases. Dr Robert Lins at SGS Clinical Research argues that improved early proof-of-concept studies should help to reduce this attrition rate.